CN113660944A - 用于补体相关疾病的融合蛋白构建体 - Google Patents

用于补体相关疾病的融合蛋白构建体 Download PDF

Info

Publication number
CN113660944A
CN113660944A CN201980091627.3A CN201980091627A CN113660944A CN 113660944 A CN113660944 A CN 113660944A CN 201980091627 A CN201980091627 A CN 201980091627A CN 113660944 A CN113660944 A CN 113660944A
Authority
CN
China
Prior art keywords
domain
polypeptide
seq
fusion protein
protein construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091627.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·柯蒂斯
M·斯托雷克
S·M·维欧雷特
S·L·凯雷德
K·C·法诺
黄成然
E·G·斯塔克
F·R·泰勒
J·A·卡拉维拉
V·M·霍勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Q32 Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Q32 Bio Inc filed Critical Q32 Bio Inc
Publication of CN113660944A publication Critical patent/CN113660944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980091627.3A 2018-12-11 2019-12-11 用于补体相关疾病的融合蛋白构建体 Pending CN113660944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778014P 2018-12-11 2018-12-11
US62/778,014 2018-12-11
PCT/US2019/065741 WO2020123662A2 (en) 2018-12-11 2019-12-11 Fusion protein constructs for complement associated disease

Publications (1)

Publication Number Publication Date
CN113660944A true CN113660944A (zh) 2021-11-16

Family

ID=71076704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091627.3A Pending CN113660944A (zh) 2018-12-11 2019-12-11 用于补体相关疾病的融合蛋白构建体

Country Status (14)

Country Link
US (4) US11053305B2 (enExample)
EP (1) EP3893916A4 (enExample)
JP (3) JP7444886B2 (enExample)
KR (2) KR20250021629A (enExample)
CN (1) CN113660944A (enExample)
AU (2) AU2019398214C1 (enExample)
GB (1) GB2583560A (enExample)
IL (1) IL283841A (enExample)
MA (1) MA54468A (enExample)
MX (2) MX2021006930A (enExample)
MY (1) MY209796A (enExample)
PH (1) PH12021551398A1 (enExample)
SG (1) SG11202106073QA (enExample)
WO (1) WO2020123662A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114778418A (zh) * 2022-06-17 2022-07-22 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
CN117624347A (zh) * 2022-08-30 2024-03-01 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
CN118373913A (zh) * 2024-05-08 2024-07-23 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119431565A (zh) * 2025-01-10 2025-02-14 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
AU2017345560C1 (en) * 2016-10-20 2025-04-17 President And Fellows Of Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
MX2021006930A (es) * 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
KR20220019806A (ko) * 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021247487A1 (en) * 2020-06-01 2021-12-09 Medical University Of South Carolina Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders
WO2021257480A2 (en) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods
WO2022010830A2 (en) * 2020-07-06 2022-01-13 President And Fellows Of Harvard College Histamine binding polypeptides and uses thereof
IL301202A (en) * 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
EP4259193A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US12522657B2 (en) 2021-06-22 2026-01-13 The General Hospital Corporation Therapeutic targeting of Cadherin 11 in cancer
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
WO2024146953A1 (en) 2023-01-05 2024-07-11 Complement Therapeutics Limited Agents and methods for treating complement diseases
IL324504A (en) * 2023-05-23 2026-01-01 4D Molecular Therapeutics Inc Antibodies that inhibit the complement system
WO2025054327A1 (en) * 2023-09-05 2025-03-13 The Regents Of The University Of Colorado, A Body Corporate Constructs, compositions, and methods for reducing hypersensitivity reactions to therapeutic agents
AU2024373907A1 (en) * 2023-10-30 2026-05-14 Akebia Therapeutics, Inc. Treatment of anca-associated vasculitis
AU2024370039A1 (en) * 2023-10-30 2026-05-28 Akebia Therapeutics, Inc. Treatment of complement-associated renal diseases
AU2024384696A1 (en) * 2023-11-24 2026-06-04 Universität Ulm Complement modulator
EP4559472A1 (en) * 2023-11-24 2025-05-28 Universität Ulm Complement modulator
TW202606662A (zh) 2024-04-26 2026-02-16 美商美國禮來大藥廠 蛋白質酪胺酸激酶7抗體及抗體藥物結合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142191A1 (en) * 2004-10-08 2006-06-29 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
WO2014028865A1 (en) * 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US20180057597A1 (en) * 2015-01-23 2018-03-01 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
CN108350086A (zh) * 2013-01-23 2018-07-31 南卡罗来纳医科大学研究发展基金会 基于天然抗体的靶向构建体及其用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US20010018051A1 (en) 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
EP3056516A1 (en) 1998-02-20 2016-08-17 Genentech, Inc. Inhibitors of complement activation
WO2001080883A1 (en) * 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
CA2471938A1 (en) * 2001-12-28 2003-07-17 Kyowa Hakko Kogyo Co., Ltd. Agent for treating arthritis
EP1594541A4 (en) 2003-02-21 2007-03-28 Rikshospitalet Radiumhospitale METHOD AND COMPOSITIONS FOR TREATING MECONIUM ASPIRATION SYNDROME
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
US20110014270A1 (en) 2006-03-27 2011-01-20 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury and related conditions
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
BR112012033119A2 (pt) * 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20120122107A1 (en) 2010-11-16 2012-05-17 Aarhus Universitet Homeostatic multidomain protein, and uses for it
WO2012075023A2 (en) 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
BR112016011195A2 (pt) * 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
WO2015105973A1 (en) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
CN106456744A (zh) * 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
AU2015269348C1 (en) 2014-06-05 2021-11-18 The Regents Of The University Of Colorado, A Body Corporate MAp44 polypeptides and constructs based on natural antibodies and uses thereof
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142191A1 (en) * 2004-10-08 2006-06-29 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
WO2014028865A1 (en) * 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CN108350086A (zh) * 2013-01-23 2018-07-31 南卡罗来纳医科大学研究发展基金会 基于天然抗体的靶向构建体及其用途
US20180057597A1 (en) * 2015-01-23 2018-03-01 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114778418A (zh) * 2022-06-17 2022-07-22 深圳安侣医学科技有限公司 基于显微放大数字图像的血红蛋白分析方法及系统
CN117624347A (zh) * 2022-08-30 2024-03-01 天辰生物医药(苏州)有限公司 抗人补体c5抗体以及其融合蛋白
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
CN118373913A (zh) * 2024-05-08 2024-07-23 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118878672A (zh) * 2024-08-01 2024-11-01 河北康立德生物科技有限公司 一种抗曲霉半乳甘露聚糖单克隆抗体、试剂盒及其应用
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119638823B (zh) * 2024-12-10 2026-05-26 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用
CN119431565A (zh) * 2025-01-10 2025-02-14 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用
CN119431565B (zh) * 2025-01-10 2025-04-08 成都迈科康生物科技有限公司 一种抗hpv16型e6蛋白和e7蛋白的抗体、检测产品及其应用

Also Published As

Publication number Publication date
KR20250021629A (ko) 2025-02-13
MY209796A (en) 2025-08-05
US11879008B2 (en) 2024-01-23
KR20210148076A (ko) 2021-12-07
US20200181249A1 (en) 2020-06-11
JP7444886B2 (ja) 2024-03-06
US11053305B2 (en) 2021-07-06
CA3123004A1 (en) 2020-06-18
MX2021006930A (es) 2021-11-17
SG11202106073QA (en) 2021-07-29
WO2020123662A2 (en) 2020-06-18
AU2019398214C1 (en) 2024-03-28
US11053306B2 (en) 2021-07-06
IL283841A (en) 2021-07-29
JP7811315B2 (ja) 2026-02-05
MA54468A (fr) 2022-04-13
MX2026002955A (es) 2026-05-04
JP2022512234A (ja) 2022-02-02
US20210309728A1 (en) 2021-10-07
US20240301043A1 (en) 2024-09-12
KR102762828B1 (ko) 2025-02-05
AU2024201109A1 (en) 2024-03-14
AU2019398214A1 (en) 2021-07-01
PH12021551398A1 (en) 2022-11-07
JP2026053563A (ja) 2026-03-25
JP2024059791A (ja) 2024-05-01
GB2583560A (en) 2020-11-04
EP3893916A4 (en) 2023-03-29
GB202001360D0 (en) 2020-03-18
EP3893916A2 (en) 2021-10-20
WO2020123662A3 (en) 2020-07-23
US20210009669A1 (en) 2021-01-14
AU2019398214B2 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
CN102459333B (zh) 抗-Tau pS422抗体用于治疗脑病的应用
JP7684803B2 (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
TW201843180A (zh) 具有肌營養不良蛋白聚糖和層黏連結蛋白－２特異性的多特異性結合分子
KR20190003951A (ko) 항-보체 인자 bb 항체 및 이의 용도
US12344663B2 (en) Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
JP2025529954A (ja) 抗ヒト補体ｃ５抗体およびその融合タンパク質
TW202528343A (zh) 抗c2結合劑及其結合物
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом
CA3123004C (en) Fusion protein constructs for complement associated disease
EP4617287A1 (en) Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof
RU2802307C2 (ru) C3-связывающие агенты и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20260112

Address after: Massachusetts, USA

Applicant after: Akebia Therapeutics, Inc.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Applicant before: Q32 biological Co.

Country or region before: U.S.A.

TA01 Transfer of patent application right